IPSC250117C2500
- 0.05
- 0.000.00%
Century Therapeutics Newsroom
Express News | Century Therapeutics Inc: Caramel Trial With Century Is Intended to Commence in Mid-2025 Following Cta Approval
Express News | Century Therapeutics- Enters Investigator-Initiated Phase 1/2 Trial of Ipsc-Derived Ink Cell Therapy Cnty-101 in B-Cell Mediated Autoimmune Diseases
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of Its IPSC-derived INK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
William Blair Maintains Century Therapeutics(IPSC.US) With Hold Rating
Cautious Optimism on Century Therapeutics: Promising Early-Stage Developments But Awaiting Further Data
Century Therapeutics Unveils Advances in Cell Therapies
Piper Sandler Maintains Overweight on Century Therapeutics, Lowers Price Target to $4
Century Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: MetaVia (MTVA), Century Therapeutics (IPSC)
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Cuts Target Price to $4
Clear Street Launches Healthcare & Biotechnology Equity Research
Shinobi Strengthens Leadership to Propel Scalable Immune-Evasive Cell Therapies to the Clinic
Century Therapeutics Faces Termination of BMS Agreement
Bristol-Myers Squibb Notified Century Therapeutics On Dec 12 To Terminate Collaboration Agreement, Effective March 12, 2025; Co To Evaluate Opportunities In AML And Multiple Myeloma In The Context Of The Ongoing Strategic Review Of Century's...
Express News | Century Therapeutics - to Evaluate Opportunities in Aml and Multiple Myeloma
Express News | Century Therapeutics - Termination Effective March 12, 2025
Express News | Century Therapeutics- Bms Notified Co on Dec 12 to Terminate Collaboration Agreement With Century Therapeutics
Analysts Are Bullish on Top Healthcare Stocks: Keros Therapeutics (KROS), Century Therapeutics (IPSC)
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Takeda in Deal With Alloy Therapeutics to Develop Cell Therapy Platforms for Cancer